发明授权
US6100256A Use of NK-1 receptors antagonists for treating schizophrenic disorders
失效
使用NK-1受体拮抗剂治疗精神分裂症
- 专利标题： Use of NK-1 receptors antagonists for treating schizophrenic disorders
- 专利标题（中）： 使用NK-1受体拮抗剂治疗精神分裂症
-
申请号： US95782申请日： 1998-06-11
-
公开(公告)号： US6100256A公开(公告)日： 2000-08-08
- 发明人: Raymond Baker , Neil Roy Curtis , Jason Matthew Elliott , Timothy Harrison , Gregory John Hollingworth , Philip Stephen Jackson , Janusz Jozef Kulagowski , Nadia Melanie Rupniak , Eileen May Seward , Christopher John Swain , Brian John Williams
- 申请人： Raymond Baker , Neil Roy Curtis , Jason Matthew Elliott , Timothy Harrison , Gregory John Hollingworth , Philip Stephen Jackson , Janusz Jozef Kulagowski , Nadia Melanie Rupniak , Eileen May Seward , Christopher John Swain , Brian John Williams
- 申请人地址： GBX Hoddesdon
- 专利权人： Merck Sharp & Dohme Ltd.
- 当前专利权人： Merck Sharp & Dohme Ltd.
- 当前专利权人地址： GBX Hoddesdon
- 优先权： GBX9625051 19961202; GBX9701459 19970124; GBX9713715 19970627; GBX9716491 19970804; GBX9721191 19971007
- 主分类号： A61K31/00
- IPC分类号： A61K31/00 ; A61K31/395 ; A61K31/438 ; A61K31/445 ; A61K31/451 ; A61K31/5375 ; A61K31/5377 ; A61K31/675 ; A61K31/535 ; A61K31/44 ; A61K31/50 ; A61K31/505
摘要：
The present invention provides a method for the treatment or prevention of schizophrenic disorders using an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.
公开/授权文献
信息查询
